(EXEL) Exelixis - Overview
Stock: Cancer, Medicines, Tablets, Capsules, Inhibitors
| Risk 5d forecast | |
|---|---|
| Volatility | 37.9% |
| Relative Tail Risk | -21.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.65 |
| Alpha | 18.17 |
| Character TTM | |
|---|---|
| Beta | 0.601 |
| Beta Downside | 0.239 |
| Drawdowns 3y | |
|---|---|
| Max DD | 25.34% |
| CAGR/Max DD | 1.44 |
EPS (Earnings per Share)
Revenue
Description: EXEL Exelixis January 02, 2026
Exelixis, Inc. (NASDAQ:EXEL) is a U.S.–focused oncology biotech that commercializes cabozantinib-based therapies-CABOMETYX for advanced renal cell carcinoma (RCC) post-anti-angiogenic treatment and COMETRIQ for progressive/metastatic medullary thyroid cancer-while maintaining a broader pipeline of kinase inhibitors, an ADC (XB010), and a MEK inhibitor combination (COTELLIC). All marketed products share the same core molecule, cabozantinib, which blocks MET, AXL, RET, and VEGF receptors.
Beyond its approved drugs, Exelixis is advancing several late-stage candidates: zanzalintinib (next-gen TKI targeting VEGF, MET, and TAM kinases), XL309 (USP1 inhibitor for BRCA-mutated tumors), and XL495 (PKMYT1 inhibitor). The firm leverages a network of collaborations with major pharma-Roche, Takeda, Merck, Bristol-Myers Squibb, among others-to share development risk and accelerate market entry. As of FY 2023, CABOMETYX generated roughly 70 % of the company’s $1.5 billion total revenue, and COMETRIQ contributed an additional $150 million, underscoring the cash-flow reliance on a narrow product set.
Sector-level drivers that materially affect Exelixis include the expanding global RCC market (projected CAGR ≈ 6 % through 2028) and the broader biotech trend of increasing R&D intensity, with industry-average R&D spend now exceeding 20 % of sales. Exelixis’ 2024 guidance assumes a 5-6 % growth in CABOMETYX sales, contingent on maintaining market share against emerging TKIs and on the successful regulatory filing of zanzalintinib. For a deeper dive into how these dynamics translate into valuation metrics, a quick look at ValueRay’s analyst toolkit may be worthwhile.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 782.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.30 > 0.02 and ΔFCF/TA 8.49 > 1.0 |
| NWC/Revenue: 44.72% < 20% (prev 49.05%; Δ -4.33% < -1%) |
| CFO/TA 0.31 > 3% & CFO 884.3m > Net Income 782.6m |
| Net Debt (-309.4m) to EBITDA (691.8m): -0.45 < 3 |
| Current Ratio: 3.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (281.9m) vs 12m ago 0.05% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 80.11% > 50% (prev 73.57%; Δ 6.54% > 0%) |
| Interest Coverage Ratio: -2.47 > 6 (EBITDA TTM 691.8m / Interest Expense TTM -271.5m) |
Altman Z'' 3.74
| A: 0.36 (Total Current Assets 1.44b - Total Current Liabilities 405.6m) / Total Assets 2.84b |
| B: -0.03 (Retained Earnings -76.8m / Total Assets 2.84b) |
| C: 0.23 (EBIT TTM 669.7m / Avg Total Assets 2.90b) |
| D: -0.11 (Book Value of Equity -76.8m / Total Liabilities 683.1m) |
| Altman-Z'' Score: 3.74 = AA |
Beneish M -3.07
| DSRI: 1.01 (Receivables 286.9m/265.4m, Revenue 2.32b/2.17b) |
| GMI: 1.00 (GM 96.39% / 96.49%) |
| AQI: 0.89 (AQ_t 0.34 / AQ_t-1 0.38) |
| SGI: 1.07 (Revenue 2.32b / 2.17b) |
| TATA: -0.04 (NI 782.6m - CFO 884.3m) / TA 2.84b) |
| Beneish M-Score: -3.07 (Cap -4..+1) = AA |
What is the price of EXEL shares?
Over the past week, the price has changed by +2.56%, over one month by +0.69%, over three months by +3.91% and over the past year by +28.89%.
Is EXEL a buy, sell or hold?
- StrongBuy: 7
- Buy: 4
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EXEL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 47.2 | 7% |
| Analysts Target Price | 47.2 | 7% |
EXEL Fundamental Data Overview February 18, 2026
P/E Forward = 14.1643
P/S = 5.0939
P/B = 5.2751
P/EG = 2.2685
Revenue TTM = 2.32b USD
EBIT TTM = 669.7m USD
EBITDA TTM = 691.8m USD
Long Term Debt = 173.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = 173.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -309.4m USD (from netDebt column, last fiscal year)
Enterprise Value = 11.51b USD (11.82b + Debt 173.0m - CCE 482.5m)
Interest Coverage Ratio = -2.47 (Ebit TTM 669.7m / Interest Expense TTM -271.5m)
EV/FCF = 13.49x (Enterprise Value 11.51b / FCF TTM 853.2m)
FCF Yield = 7.41% (FCF TTM 853.2m / Enterprise Value 11.51b)
FCF Margin = 36.77% (FCF TTM 853.2m / Revenue TTM 2.32b)
Net Margin = 33.73% (Net Income TTM 782.6m / Revenue TTM 2.32b)
Gross Margin = unknown ((Revenue TTM 2.32b - Cost of Revenue TTM 83.7m) / Revenue TTM)
Tobins Q-Ratio = 4.05 (Enterprise Value 11.51b / Total Assets 2.84b)
Interest Expense / Debt = 15.20% (Interest Expense 26.3m / Debt 173.0m)
Taxrate = 3.23% (8.16m / 252.7m)
NOPAT = 648.1m (EBIT 669.7m * (1 - 3.23%))
Current Ratio = 3.56 (Total Current Assets 1.44b / Total Current Liabilities 405.6m)
Debt / Equity = 0.08 (Debt 173.0m / totalStockholderEquity, last quarter 2.16b)
Debt / EBITDA = -0.45 (Net Debt -309.4m / EBITDA 691.8m)
Debt / FCF = -0.36 (Net Debt -309.4m / FCF TTM 853.2m)
Total Stockholder Equity = 2.12b (last 4 quarters mean from totalStockholderEquity)
RoA = 27.02% (Net Income 782.6m / Total Assets 2.84b)
RoE = 36.89% (Net Income TTM 782.6m / Total Stockholder Equity 2.12b)
RoCE = 29.18% (EBIT 669.7m / Capital Employed (Equity 2.12b + L.T.Debt 173.0m))
RoIC = 30.55% (NOPAT 648.1m / Invested Capital 2.12b)
WACC = 8.22% (E(11.82b)/V(11.99b) * Re(8.13%) + D(173.0m)/V(11.99b) * Rd(15.20%) * (1-Tc(0.03)))
Discount Rate = 8.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -5.11%
[DCF Debug] Terminal Value 80.53% ; FCFF base≈765.4m ; Y1≈944.2m ; Y5≈1.61b
Fair Price DCF = 101.3 (EV 25.99b - Net Debt -309.4m = Equity 26.30b / Shares 259.7m; r=8.22% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 83.25 | EPS CAGR: 49.13% | SUE: 0.83 | # QB: 0
Revenue Correlation: 89.48 | Revenue CAGR: 14.87% | SUE: -0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.76 | Chg30d=+0.030 | Revisions Net=+1 | Analysts=11
EPS current Year (2026-12-31): EPS=3.39 | Chg30d=+0.034 | Revisions Net=+2 | Growth EPS=+10.2% | Growth Revenue=+11.4%
EPS next Year (2027-12-31): EPS=4.00 | Chg30d=-0.072 | Revisions Net=+2 | Growth EPS=+17.8% | Growth Revenue=+14.3%